Skip to main content
Top
Published in: Clinical Rheumatology 8/2018

01-08-2018 | Original Article

Severe infections in systemic lupus erythematosus: disease pattern and predictors of infection-related mortality

Authors: C. L. Teh, S. A. Wan, G. R. Ling

Published in: Clinical Rheumatology | Issue 8/2018

Login to get access

Abstract

Infection is a major cause of morbidity and mortality among patients with systemic lupus erythematosus (SLE). To describe the pattern of serious infections in patients with SLE and to identify the predictors of infection-related mortality among SLE patients with serious infections, we prospectively studied all SLE patients who were hospitalized with infections in Sarawak General Hospital during 2011–2015. Demographic data, clinical features, and outcomes were collected. Cox regression analysis was carried out to determine the independent predictors of infection-related mortality. There were a total of 125 patients with 187 episodes of serious infections. Our patients were of multiethnic origins with female predominance (89.6%). Their mean age was 33.4 ± 14.2 years. The patients had a mean disease duration of 66.8 ± 74.0 months. The most common site of infection was pulmonary (37.9%), followed by septicemia (22.5%). Gram-negative organisms (38.2%) were the predominant isolates within the cohort. There were 21 deaths (11.2%) during the study period. Independent predictors of infection-related mortality among our cohort of SLE patients were flare of SLE (HR 3.98, CI 1.30–12.21) and the presence of bacteremia (HR 2.54, CI 0.98–6.59). Hydroxychloroquine was protective of mortality from serious infections (HR 9.26, CI 3.40–25.64). Pneumonia and Gram-negative organisms were the predominant pattern of infection in our SLE cohort. The presence of flare of SLE and bacteremia were independent prognostic predictors of infection-related mortality, whereas hydroxychloroquine was protective of infection-related mortality among SLE patients with serious infections.
Literature
1.
go back to reference Lee J, Dhillon N, Pope J (2013) All-cause hospitalizations in systemic lupus erythematosus from a large Canadian referral centre. Rheumatology (Oxford) 52:905–909CrossRef Lee J, Dhillon N, Pope J (2013) All-cause hospitalizations in systemic lupus erythematosus from a large Canadian referral centre. Rheumatology (Oxford) 52:905–909CrossRef
2.
go back to reference Feldman CH, Hiraki LT, Winkelmayer WC, Marty FM, Franklin JM, Kim SC, Costenbader KH (2015) Serious infections among adult Medicaid beneficiaries with systemic lupus erythematosus and lupus nephritis. Arthritis Rheumatol 7(6):1577–1585CrossRef Feldman CH, Hiraki LT, Winkelmayer WC, Marty FM, Franklin JM, Kim SC, Costenbader KH (2015) Serious infections among adult Medicaid beneficiaries with systemic lupus erythematosus and lupus nephritis. Arthritis Rheumatol 7(6):1577–1585CrossRef
3.
go back to reference Goldblatt F, Chambers S, Rahman A, Isenberg DA (2009) Serious infections in British patients with systemic lupus erythematosus: hospitalisations and mortality. Lupus 18:682–689CrossRefPubMed Goldblatt F, Chambers S, Rahman A, Isenberg DA (2009) Serious infections in British patients with systemic lupus erythematosus: hospitalisations and mortality. Lupus 18:682–689CrossRefPubMed
4.
go back to reference Gladman DD, Hussain F, Ibanez D, Urowitz MB (2002) The nature and outcome of infection in systemic lupus erythematosus. Lupus 11:234–239CrossRefPubMed Gladman DD, Hussain F, Ibanez D, Urowitz MB (2002) The nature and outcome of infection in systemic lupus erythematosus. Lupus 11:234–239CrossRefPubMed
5.
go back to reference Petri M, Genovese M (1992) Incidence of and risk factors for hospitalizations in systemic lupus erythematosus: a prospective study of the Hopkins lupus cohort. J Rheumatol 19:1559–1565PubMed Petri M, Genovese M (1992) Incidence of and risk factors for hospitalizations in systemic lupus erythematosus: a prospective study of the Hopkins lupus cohort. J Rheumatol 19:1559–1565PubMed
6.
go back to reference Chen D, Xie J, Chen H, Yang Y, Zhan Z, Liang L, Yang X (2016) Infection in southern Chinese patients with systemic lupus erythematosus: spectrum, drug resistance, outcomes, and risk factors. J Rheumatol 43(9):1650–1656CrossRefPubMed Chen D, Xie J, Chen H, Yang Y, Zhan Z, Liang L, Yang X (2016) Infection in southern Chinese patients with systemic lupus erythematosus: spectrum, drug resistance, outcomes, and risk factors. J Rheumatol 43(9):1650–1656CrossRefPubMed
7.
go back to reference Alarcon GS, Jr MGG, Bastian HM, Roseman J, Lisse J, Fessler BJ et al (2001) For the LUMINA study Group Systemic lupus erythematosus in three ethnic groups. VIII. Predictors of early mortality in the LUMINA cohort. Arthritis Rheum 45:191–202CrossRefPubMed Alarcon GS, Jr MGG, Bastian HM, Roseman J, Lisse J, Fessler BJ et al (2001) For the LUMINA study Group Systemic lupus erythematosus in three ethnic groups. VIII. Predictors of early mortality in the LUMINA cohort. Arthritis Rheum 45:191–202CrossRefPubMed
8.
go back to reference Dubula T, Mody GM (2015) Spectrum of infections and outcome among hospitalized south Africans with systemic lupus erythematosus. Clin Rheumatol 34(3):479–488CrossRefPubMed Dubula T, Mody GM (2015) Spectrum of infections and outcome among hospitalized south Africans with systemic lupus erythematosus. Clin Rheumatol 34(3):479–488CrossRefPubMed
9.
go back to reference Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I, Martinez-Berriotxoa A, Egurbide MV, Aguirre C (2009) Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther 11:R109CrossRefPubMedPubMedCentral Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I, Martinez-Berriotxoa A, Egurbide MV, Aguirre C (2009) Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther 11:R109CrossRefPubMedPubMedCentral
10.
go back to reference Tektonidou MG, Wang Z, Dasgupta A, Ward MM (2015) Burden of serious infections in adults with systemic lupus erythematosus: a National Population-Based Study, 1996–2011. Arthritis Care Res 67(8):1078–1085CrossRef Tektonidou MG, Wang Z, Dasgupta A, Ward MM (2015) Burden of serious infections in adults with systemic lupus erythematosus: a National Population-Based Study, 1996–2011. Arthritis Care Res 67(8):1078–1085CrossRef
11.
go back to reference Yurkovich M, Vostretsova K, Chen W, Avina-Zubieta JA (2014) Overall and cause-specific mortality in patients with systemic lupus erythematosus: a meta-analysis of observational studies. Arthritis Care Res 66:608–616CrossRef Yurkovich M, Vostretsova K, Chen W, Avina-Zubieta JA (2014) Overall and cause-specific mortality in patients with systemic lupus erythematosus: a meta-analysis of observational studies. Arthritis Care Res 66:608–616CrossRef
12.
go back to reference Tan EM, Cohen AS, Fries JF, Masi AT, Mcshane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277CrossRefPubMed Tan EM, Cohen AS, Fries JF, Masi AT, Mcshane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277CrossRefPubMed
13.
go back to reference Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) The committee on prognosis studies in SLE. The development and validation of the SLE disease activity index (SLEDAI). Arthritis Rheum 35:630–640CrossRefPubMed Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) The committee on prognosis studies in SLE. The development and validation of the SLE disease activity index (SLEDAI). Arthritis Rheum 35:630–640CrossRefPubMed
14.
go back to reference Buyon JP, Petri MA, Kim MY, Kalunian KC, Grossman J, Hahn BH et al (2005) The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med 142:953–962CrossRefPubMed Buyon JP, Petri MA, Kim MY, Kalunian KC, Grossman J, Hahn BH et al (2005) The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med 142:953–962CrossRefPubMed
15.
go back to reference Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Sanchez-Guerrero J, Urowitz M, Bacon P, Bombardieri S, Hanly J, Jones J, Hay E, Symmons D, Isenberg D, Kalunion K, Maddison P, Nived O, Sturfelt G, Petri M, Richter M, Snaith M, Zoma A (1996) The development and initial validation of the SLICC/ACR damage index for SLE. Arthritis Rheum 39:363–369CrossRefPubMed Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Sanchez-Guerrero J, Urowitz M, Bacon P, Bombardieri S, Hanly J, Jones J, Hay E, Symmons D, Isenberg D, Kalunion K, Maddison P, Nived O, Sturfelt G, Petri M, Richter M, Snaith M, Zoma A (1996) The development and initial validation of the SLICC/ACR damage index for SLE. Arthritis Rheum 39:363–369CrossRefPubMed
16.
go back to reference Lim E, Koh WH, Loh SF, Lam MS, Howe HS (2001) Nonthyphoidal salmonellosis in patients with systemic lupus erythematosus. A study of fifty patients and a review of the literature. Lupus 10:87–92CrossRefPubMed Lim E, Koh WH, Loh SF, Lam MS, Howe HS (2001) Nonthyphoidal salmonellosis in patients with systemic lupus erythematosus. A study of fifty patients and a review of the literature. Lupus 10:87–92CrossRefPubMed
17.
go back to reference Gerona JG, Navarra SV (2009) Salmonella infections in patients with systemic lupus erythematosus: a case series. Int J Rheum Dis 12(4):319–323CrossRefPubMed Gerona JG, Navarra SV (2009) Salmonella infections in patients with systemic lupus erythematosus: a case series. Int J Rheum Dis 12(4):319–323CrossRefPubMed
18.
go back to reference Yun JE, Lee SW, Kim TH, Jun JB, Jung S, Bae SC, Kim TY, Yoo DH (2002) The incidence and clinical characteristics of Mycobacterium tuberculosis infection among systemic lupus erythematosus and rheumatoid arthritis patients in Korea. Clin Exp Rheumatol 20:127–132PubMed Yun JE, Lee SW, Kim TH, Jun JB, Jung S, Bae SC, Kim TY, Yoo DH (2002) The incidence and clinical characteristics of Mycobacterium tuberculosis infection among systemic lupus erythematosus and rheumatoid arthritis patients in Korea. Clin Exp Rheumatol 20:127–132PubMed
19.
go back to reference Sayarlioglu M, Inanc M, al KS (2004) Tuberculosis in Turkish patients with systemic lupus erythematosus: increased frequency of extrapulmonary localization. Lupus 13:274–278CrossRefPubMed Sayarlioglu M, Inanc M, al KS (2004) Tuberculosis in Turkish patients with systemic lupus erythematosus: increased frequency of extrapulmonary localization. Lupus 13:274–278CrossRefPubMed
20.
go back to reference Lim CC, Liu PY, Tan HZ, Lee P, Chin YM, Mok IY, Chan CM, Choo JC (2016) Severe infections in patients with lupus nephritis treated with immunosuppressants: a retrospective cohort study. Nephrology Lim CC, Liu PY, Tan HZ, Lee P, Chin YM, Mok IY, Chan CM, Choo JC (2016) Severe infections in patients with lupus nephritis treated with immunosuppressants: a retrospective cohort study. Nephrology
21.
go back to reference Hellmann DB, Petri M, Whiting-O’Keefe Q (1987) Fatal infections in systemic lupus erythematosus: the role of opportunistic organisms. Medicine (Baltimore) 66(5):341–348CrossRef Hellmann DB, Petri M, Whiting-O’Keefe Q (1987) Fatal infections in systemic lupus erythematosus: the role of opportunistic organisms. Medicine (Baltimore) 66(5):341–348CrossRef
22.
go back to reference Zonana-Nacach A, Yañez P, Jiménez-Balderas FJ, Camargo-Coronel A (2007) Disease activity, damage and survival in Mexican patients with acute severe systemic lupus erythematosus. Lupus 16(12):997–1000CrossRefPubMed Zonana-Nacach A, Yañez P, Jiménez-Balderas FJ, Camargo-Coronel A (2007) Disease activity, damage and survival in Mexican patients with acute severe systemic lupus erythematosus. Lupus 16(12):997–1000CrossRefPubMed
23.
go back to reference Paton NI, Cheong IK, Kong NC, Segasothy M (1996) Risk factors for infection in Malaysian patients with systemic lupus erythematosus. QJM 89(7):531–538CrossRefPubMed Paton NI, Cheong IK, Kong NC, Segasothy M (1996) Risk factors for infection in Malaysian patients with systemic lupus erythematosus. QJM 89(7):531–538CrossRefPubMed
24.
go back to reference Bosch X, Guilabert A, Pallares L et al (2006) Infections in systemic lupus erythematosus: a prospective and controlled study of 110 patients. Lupus 15:584–589CrossRefPubMed Bosch X, Guilabert A, Pallares L et al (2006) Infections in systemic lupus erythematosus: a prospective and controlled study of 110 patients. Lupus 15:584–589CrossRefPubMed
25.
go back to reference Rúa-Figueroa Í, López-Longo J, Galindo-Izquierdo M, Calvo-Alén J, Del Campo V, Olivé-Marqués A et al (2017) Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus. Semin Arthritis Rheum Rúa-Figueroa Í, López-Longo J, Galindo-Izquierdo M, Calvo-Alén J, Del Campo V, Olivé-Marqués A et al (2017) Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus. Semin Arthritis Rheum
26.
go back to reference Chen MJ, Tseng HM, Huang YL, Hsu WN, Yeh KW, Wu TL, See LC, Huang JL (2008) Long-term outcome and short-term survival of patients with systemic lupus erythematosus after bacteraemia episodes: 6-yr follow-up. Rheumatology (Oxford) 47:1352–1357CrossRef Chen MJ, Tseng HM, Huang YL, Hsu WN, Yeh KW, Wu TL, See LC, Huang JL (2008) Long-term outcome and short-term survival of patients with systemic lupus erythematosus after bacteraemia episodes: 6-yr follow-up. Rheumatology (Oxford) 47:1352–1357CrossRef
27.
go back to reference Marcos M, Fernández C, Soriano A, Fernández C, Soriano À, Marco F, Martínez JA, Almela M, Cervera R, Mensa J, Espinosa G (2011) Epidemiology and clinical outcomes of bloodstream infections among lupus patients. Lupus 20:965–971CrossRefPubMed Marcos M, Fernández C, Soriano A, Fernández C, Soriano À, Marco F, Martínez JA, Almela M, Cervera R, Mensa J, Espinosa G (2011) Epidemiology and clinical outcomes of bloodstream infections among lupus patients. Lupus 20:965–971CrossRefPubMed
28.
go back to reference Feldman CH, Marty FM, Winkelmayer WC, Guan H, Franklin JM, Solomon DH, Costenbader KH, Kim SC (2017) Comparative rates of serious infections among patients with systemic lupus erythematosus receiving immunosuppressive medications. Arthritis Rheumatol 69(2):387–397CrossRefPubMedPubMedCentral Feldman CH, Marty FM, Winkelmayer WC, Guan H, Franklin JM, Solomon DH, Costenbader KH, Kim SC (2017) Comparative rates of serious infections among patients with systemic lupus erythematosus receiving immunosuppressive medications. Arthritis Rheumatol 69(2):387–397CrossRefPubMedPubMedCentral
29.
go back to reference Herrinton LJ, Liu L, Goldfien R, Michaels MA, Tran TN (2016) Risk of serious infection for patients with systemic lupus erythematosus starting glucocorticoids with or without antimalarials. J Rheumatol 43(8):1503–1509CrossRefPubMed Herrinton LJ, Liu L, Goldfien R, Michaels MA, Tran TN (2016) Risk of serious infection for patients with systemic lupus erythematosus starting glucocorticoids with or without antimalarials. J Rheumatol 43(8):1503–1509CrossRefPubMed
Metadata
Title
Severe infections in systemic lupus erythematosus: disease pattern and predictors of infection-related mortality
Authors
C. L. Teh
S. A. Wan
G. R. Ling
Publication date
01-08-2018
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 8/2018
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-018-4102-6

Other articles of this Issue 8/2018

Clinical Rheumatology 8/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.